Nektar Therapeutics (NKTR) vs Ultragenyx Pharmaceutical (RARE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nektar Therapeutics (NKTR) has outperformed Ultragenyx Pharmaceutical (RARE) over the past year, losing 27.9% versus a loss of 50.5%. Over five years, RARE leads with a -80.9% price change compared with -84.3% for NKTR. Ultragenyx Pharmaceutical is the larger company by market cap ($1.53 billion vs $1.41 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NKTR | RARE |
|---|---|---|
| Share price | $41.17 | $15.48 |
| Market cap | $1.41B | $1.53B |
| 1-day change | +0.91% | +1.24% |
| YTD return | -3.50% | -33.52% |
| 1-year return | -27.86% | -50.45% |
| 5-year return | -84.29% | -80.89% |
| Forward P/E | — | 22.87 |
| EPS (TTM) | $-18.96 | $-5.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $673.00M |
| Revenue growth (YoY) | — | +20.18% |
| Net income (latest FY) | — | $-575.00M |
| Operating margin | — | -79.49% |
| Net margin | — | -85.44% |
| 52-week high | $109.00 | $39.89 |
| 52-week low | $33.40 | $12.73 |
| Distance from 52-week high | -62.23% | -61.19% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +243.45% | +81.20% |
| Average volume | 1.07M | 3.87M |
| Shares outstanding | 34.14M | 98.59M |
| Employees | 63 | 1,371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NKTR has outperformed RARE by 22.6 percentage points over the past year.
About Nektar Therapeutics
NKTR stock →Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
About Ultragenyx Pharmaceutical
RARE stock →Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,371 employees
NKTR vs RARE FAQ
Which is bigger, Nektar Therapeutics or Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical (RARE) is larger, with a market capitalization of $1.53B compared with $1.41B for Nektar Therapeutics (NKTR).
Which stock has performed better over the past year, NKTR or RARE?
NKTR returned -27.86% over the past 12 months, compared with -50.45% for RARE (price return, excluding dividends). Past performance does not predict future results.
Are Nektar Therapeutics and Ultragenyx Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.